Alpha Tau Medical Ltd. (DRTS)
NASDAQ: DRTS · Real-Time Price · USD
10.36
-0.05 (-0.48%)
At close: May 15, 2026, 4:00 PM EDT
10.52
+0.16 (1.54%)
After-hours: May 15, 2026, 7:58 PM EDT
Alpha Tau Medical Employees
Alpha Tau Medical had 121 employees as of December 31, 2025. The number of employees decreased by 4 or -3.20% compared to the previous year.
Employees
121
Change (1Y)
-4
Growth (1Y)
-3.20%
Revenue / Employee
n/a
Profits / Employee
-$352,289
Market Cap
911.78M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 121 | -4 | -3.20% |
| Dec 31, 2024 | 125 | 4 | 3.31% |
| Dec 31, 2023 | 121 | 27 | 28.72% |
| Dec 31, 2022 | 94 | 11 | 13.25% |
| Dec 31, 2021 | 83 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| Pharming Group | 407 |
| MeiraGTx Holdings | 403 |
| Phathom Pharmaceuticals | 371 |
| Omeros | 175 |
| Sana Biotechnology | 142 |
| Cullinan Therapeutics | 109 |
| Annexon | 93 |
DRTS News
- 3 days ago - Alpha Tau price target raised to $14 from $12 at Ladenburg - TheFly
- 4 days ago - Alpha Tau price target raised to $15 from $12 at H.C. Wainwright - TheFly
- 4 days ago - Alpha Tau Medical Transcript: Study result - Transcripts
- 4 days ago - Alpha Tau announces interim data from REGAIN trial - TheFly
- 4 days ago - Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET - GlobeNewsWire
- 7 days ago - Alpha Tau completes enrollment in ReSTART trial - TheFly
- 7 days ago - Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma - GlobeNewsWire
- 7 days ago - Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma - GlobeNewsWire